Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION adjuvant chemotherapy in older women with early breast cancer
ISRCTN41708421Phase 3Terminated
- Sponsor
- The Institute of Cancer Research
- Start
- Feb 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, epirubicin, cyclophosphamide and pegylated G-CSF in breast cancer (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Relapse free interval. Started Feb 2006; status: terminated.
02
Drugs
doxorubicinepirubicincyclophosphamidepegylated G-CSF
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN41708421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN41708421.